A Phase 2 interventional study of GSK3036656 and Rifafour e-275 in Tuberculosis, sponsored by GlaxoSmithKline. Completed at 1 site in South Africa. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-10-26.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Tuberculosis, Pulmonary with a site in South Africa — 10 open to participants now, 13 under way, 3 of them phase 3. Tuberculosis, Pulmonary · South Africa.
Among the 78 studies in Tuberculosis, Pulmonary with a site in South Africa, this one is the 51st largest by enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2019, is one of 49 in phase 2, and was the 33rd registered.
319 studies on the registry are indexed under Tuberculosis, Pulmonary; 71 are open to participants now.
Browse Tuberculosis, Pulmonary studies →10 of the 78 studies in Tuberculosis, Pulmonary with a site in South Africa are open now. Recruiting first, the newest first:
North-West University, South Africa · Sites in South Africa
Ages 18–45
Global Alliance for TB Drug Development · Sites in South Africa, Tanzania
Ages 18–65
Gates Medical Research Institute · Sites in South Africa
Ages 18–65
Thirty Respiratory Limited · Sites in South Africa
Ages 18–65
TASK Applied Science · Sites in South Africa
Ages 18–65
A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →
Of the 46 Tuberculosis, Pulmonary studies recruiting now, 22 (48%) set no upper age limit and 20 (43%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 57 · Phase 3 11
First in 2003; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is below the median of 146 across 227 interventional studies indexed under Tuberculosis, Pulmonary.
Median enrollment 122 across the 67 interventional studies, 900 across the 11 observational. Of the 57 that completed or were terminated, 31 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 78 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 2 studies filed under Tuberculosis, Pulmonary — fewer than ten, so there is no comparison to draw.
6 of the studies in Tuberculosis, Pulmonary with a site in South Africa that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05766267Phase 3Centers for Disease Control and PreventionShort-course Regimens for the Treatment of Pulmonary Tuberculosis | 2026-12-31 |
| NCT06253715Phase 3Johns Hopkins UniversityShortened Regimen for Drug-susceptible TB in Children | 2027-09-30 |
| NCT06114628University College, LondonPlatform Assessing Regimens and Durations In a Global Multisite Consortium for TB | 2027-02-24 |
| NCT07672405Global Alliance for TB Drug DevelopmentSorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB | 2027-05-28 |
| NCT05807399Michael HoelscherPanACEA - STEP2C -01 | 2027-10-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 78 studies in Tuberculosis, Pulmonary with a site in South Africa, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Tuberculosis remains a concerning health problem, with Mycobacterium Tuberculosis (MTB) now causing more deaths than acquired immune deficiency syndrome (AIDS). GSK3036656 is a compound with a novel mechanism of action under development for the treatment of tuberculosis. It suppresses protein synthesis in MTB by selectively inhibiting the enzyme Leucyl t-ribose nucleic acid (RNA) synthetase. Thus, this study will investigate the early bactericidal activity, safety and tolerability of GSK3036656 in up to four sequential cohorts of subjects with rifampicin-susceptible tuberculosis. The primary objective of this dose-escalation study is to establish the anti-tuberculosis effect of GSK3036656 on serial colony forming units (CFU) counts of MTB in sputum over 14 days of therapy. Subjects in each cohort will be randomized in 3:1 ratio to one of two treatments: either GSK3036656 or standard-of-care (RIFAFOUR® e-275) regimen. The approximate duration of the study for an individual subject will be 5 weeks, including 1 week of screening, 2 weeks of treatment period and another 2 weeks of final follow-up visit. RIFAFOUR e-275 is a registered trademark of Sanofi-Aventis.
319 studies on the registry are indexed under Tuberculosis, Pulmonary; 71 are open to participants now.
This study's enrollment of 76 is below the median of 146 across 227 interventional studies indexed under Tuberculosis, Pulmonary.
Browse Tuberculosis, Pulmonary studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Tuberculosis, Pulmonary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tuberculosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive a standard-of-care therapy (rifafour e-275) tablet, orally, once daily from Day 1 to Day 14. Participants will receive the standard treatment for tuberculosis (i.e. rifafour e-275 or equivalent generic alternative) once the study treatment (Day 1 to Day 14) is completed.
Drug: Rifafour e-275
Participants will receive a loading dose of GSK3036656 3 milligram (mg), capsule, orally on Day 1, followed by maintenance dose of GSK3036656 1 mg, orally, once daily from Day 2 to Day 14.
Drug: GSK3036656
Participants will receive a loading dose of GSK3036656 15 mg, capsule, orally on Day 1, followed by maintenance dose of GSK3036656 5 mg, orally, once daily from Day 2 to Day 14.
Drug: GSK3036656
Participants will receive a loading dose of GSK3036656 30 mg, capsule, orally on Day 1, followed by maintenance dose of GSK3036656 15 mg, orally, once daily from Day 2 to Day 14.
Drug: GSK3036656
Participants will receive a loading dose of GSK3036656 75 mg, capsule, orally on Day 1, followed by maintenance dose of GSK3036656 30 mg, orally, once daily from Day 2 to Day 14.
Drug: GSK3036656
GSK3036656 will be administered
Drug pages: Isoniazid · Rifampin · Pyrazinamide · Ethambutol
Rifafour e-275 will be administered
Change in log10 Colony Forming Units (CFU) Per (/) Milliliter (mL) of Direct Respiratory Sputum Samples From Baseline to Day 14
The Early Bactericidal Activity was determined by change in log10CFU/mL of sputum over the period Baseline to Day 14. Log(CFU) was calculated as: Log(CFU/mL)=log10(mean\[Total count 1:Total Count 2\]\*2\*5\*10\^Dilution); where total counts 1 and 2 were bacterial counts from plates 1 and 2 respectively; \*2 represents the 1:1 dilution of the original specimen and \*5 represents the 0.2 mL (200 microliter) inoculation of the specimen; Dilution is the dilution factor for that plate. Baseline (Day 0) was defined as the mean of Day -2 and Day -1; if data was available at only one of these timepoints then that value was used as Baseline.
Time frame: Baseline and up to Day 14
Change in log10 CFU/mL of Direct Respiratory Sputum Samples From Baseline to Day 2
The Early Bactericidal Activity was determined by change in log10CFU per mL of sputum over the period Baseline to Day 2. Log(CFU) was calculated as: Log(CFU/mL)=log10(mean\[Total count 1:Total Count 2\]\*2\*5\*10\^Dilution); where total counts 1 and 2 were bacterial counts from plates 1 and 2 respectively; \*2 represents the 1:1 dilution of the original specimen and \*5 represents the 0.2 mL (200 microliter) inoculation of the specimen; Dilution is the dilution factor for that plate. Baseline (Day 0) was defined as the mean of Day -2 and Day -1; if data was available at only one of these timepoints then that value was used as Baseline.
Time frame: Baseline and up to Day 2
Change in log10 CFU Per mL of Direct Respiratory Sputum Samples From Day 2 to Day 14
The Early Bactericidal Activity was determined by change in log10CFU per mL of sputum over the period Day 2 to Day 14. Log(CFU) was calculated as: Log(CFU/mL)=log10(mean\[Total count 1:Total Count 2\]\*2\*5\*10\^Dilution); where total counts 1 and 2 were bacterial counts from plates 1 and 2 respectively; \*2 represents the 1:1 dilution of the original specimen and \*5 represents the 0.2 mL (200 microliter) inoculation of the specimen; Dilution is the dilution factor for that plate.
Time frame: Day 2 to Day 14
Change in log10 Time to Sputum Culture Positivity (TTP) From Baseline to Day 14
The Early Bactericidal Activity was determined by change in TTP per mL sputum over the period Baseline to Day 14. The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) automated liquid culture system of time to positivity of Mycobacterium tuberculosis from an overnight sputum collection. Time to sputum-culture positivity was the time between sample inoculation and detection of mycobacterial growth in the mycobacterium growth indicator tube. Baseline (Day 0) was defined as the mean of Day -2 and Day -1; if data was available at only one of these timepoints then that value was used as Baseline.
Time frame: Baseline and up to Day 14
Change in log10 TTP From Baseline to Day 2
The Early Bactericidal Activity was determined by change in TTP per mL sputum over the period Baseline to Day 2. The TTP was measured in the MGIT automated liquid culture system of time to positivity of Mycobacterium tuberculosis from an overnight sputum collection. Time to sputum-culture positivity was the time between sample inoculation and detection of mycobacterial growth in the mycobacterium growth indicator tube. Baseline (Day 0) was defined as the mean of Day -2 and Day -1; if data was available at only one of these timepoints then that value was used as Baseline.
Time frame: Baseline and up to Day 2
Change in log10 TTP From Day 2 to Day 14
The Early Bactericidal Activity was determined by change in TTP per mL sputum over the period Day 2 to Day 14. The TTP was measured in the MGIT automated liquid culture system of time to positivity of Mycobacterium tuberculosis from an overnight sputum collection. Time to sputum-culture positivity was the time between sample inoculation and detection of mycobacterial growth in the mycobacterium growth indicator tube.
Time frame: Day 2 to Day 14
Area Under the Plasma Drug Concentration Versus Time Curve From Time Zero to Last Time of Quantifiable Concentration (AUC[0-t]) Following Once Daily Dosing of GSK3036656
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3036656.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 14
Area Under the Plasma Concentration Time Curve From Zero to 24 Hours (AUC[0-24]) Following Once Daily Dosing of GSK3036656
Blood samples were collected at indicated time points for PK analysis of GSK3036656.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 14
Maximum Observed Plasma Drug Concentration (Cmax) Following Once Daily Dosing of GSK3036656
Blood samples were collected at indicated time points for PK analysis of GSK3036656.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 14
Time to Reach Cmax (Tmax) Following Once Daily Dosing of GSK3036656
Blood samples were collected at indicated time points for PK analysis of GSK3036656.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 14
Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Adverse events which were not Serious Adverse Events were considered as Non-Serious adverse events.
Time frame: Up to Day 28 (follow-up visit)
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count
Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, total neutrophils, and platelet count. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
Time frame: Baseline (Day 1, Pre-dose) and at Day 14
Change From Baseline in Hematology Parameter: Hemoglobin
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
Time frame: Baseline (Day 1, Pre-dose) and at Day 14
Change From Baseline in Hematology Parameter: Hematocrit
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
Time frame: Baseline (Day 1, Pre-dose) and at Day 14
Change From Baseline in Hematology Parameter: Red Blood Cells Count
Blood samples were collected to analyze the hematology parameter: red blood cells count. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
Time frame: Baseline (Day 1, Pre-dose) and at Day 14
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume
Blood samples were collected to analyze the hematology parameter: mean corpuscular volume. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
Time frame: Baseline (Day 1, Pre-dose) and at Day 14
Change From Baseline in Hematology Parameter: Mean Corpuscle Hemoglobin
Blood samples were collected to analyze the hematology parameter: mean corpuscle hemoglobin. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
Time frame: Baseline (Day 1, Pre-dose) and at Day 14
Change From Baseline in Hematology Parameter: Reticulocytes
Blood samples were collected to analyze the hematology parameter: reticulocytes. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
Time frame: Baseline (Day 1, Pre-dose) and at Day 14
Change From Baseline in Chemistry Parameters: Glucose, Calcium, Chloride, Potassium, Sodium, Blood Urea Nitrogen
Blood samples were collected to analyze the chemistry parameters: glucose, calcium, chloride, potassium, sodium, and blood urea nitrogen. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
Time frame: Baseline (Day 1, Pre-dose) and at Day 14
Change From Baseline in Chemistry Parameters: Lactate Dehydrogenase (LDH), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT)
Blood samples were collected to analyze the chemistry parameters: LDH, ALT, ALP, AST and GGT. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
Time frame: Baseline (Day 1, Pre-dose) and at Day 14
Change From Baseline in Chemistry Parameters: Creatinine, Indirect Bilirubin, Direct Bilirubin and Total Bilirubin
Blood samples were collected to analyze the chemistry parameters: creatinine, indirect bilirubin, direct bilirubin and total bilirubin. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
Time frame: Baseline (Day 1, Pre-dose) and at Day 14
Change From Baseline in Chemistry Parameter: Total Protein
Blood samples were collected to analyze the chemistry parameter: total protein. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
Time frame: Baseline (Day 1, Pre-dose) and at Day 14
Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method
Urine samples were collected to assess urine occult blood and urine protein. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased and increase to abnormal for urine occult blood and protein indicating proportional concentrations in the urine sample. 'No change/decreased' means no change from Baseline or a value less than the Baseline value. 'Increase to abnormal' means an increase from the Baseline value that is considered as an abnormal value. Baseline value is the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Data for worst-case post Baseline is presented.
Time frame: Baseline (Day 1, Pre-dose) and up to Day 28 (follow-up visit)
Number of Participants With Worst Case Vital Sign Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline
Vital signs were measured in a semi-supine or supine position after 5 minutes rest. The PCI range for vital signs were: systolic blood pressure (SBP) (lower: \<85 and upper: \>160 milliliter of mercury \[mmHg\]); diastolic blood pressure (DBP) (lower: \<45 and upper: \>100 mmHg); heart rate (lower: \<40 and upper: \>110 beats per minute \[bpm\]); respiratory rate (lower: 10 and upper: 28 breaths per minutes) and temperature (lower: \<35 and upper: \>37.9 degrees Celsius). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high), unless there was no change in their category. Participants whose value category was unchanged (e.g. High to High), or whose value became within range, were recorded in the "To w/in Range or No Change category". Participants were counted twice if the participant had values that changed "To Low" and "To High".
Time frame: Up to Day 28 (follow-up visit)
Number of Participants With Worst Case Post-Baseline Abnormal Electrocardiogram (ECG) Findings
Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, uncorrected QT and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Abnormal findings were categorized as clinically significant and not clinically significant. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with abnormal clinically significant ECG findings for worst case post-Baseline has been presented.
Time frame: Up to Day 28 (follow-up visit)
Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF)
Twelve-lead ECGs were obtained to QTcF Interval and measured QT duration corrected for heart rate by Fridericia's formula interval. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits and the mean of the triplicate measurements at any given time point was used as the value for that time point. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
Time frame: Baseline (Day 1, Pre-dose) and at Day 14
This was an open-label trial to investigate the early bactericidal activity, safety and tolerability of GSK3036656 in participants with drug-sensitive pulmonary tuberculosis. Participants received Rifafour e-275 as a standard-of-care or GSK3036656. Rifafour e-275 is a registered trademark of Sanofi-Aventis company.
| Milestone | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Started | 18 | 9 | 17 | 16 | 16 |
| Safety population consisted of all randomized participants who received at least 1 dose of treatment | 18 | 9 | 17 | 16 | 15 |
| Completed | 18 | 8 | 15 | 15 | 13 |
| Not completed | 0 | 1 | 2 | 1 | 3 |
| Withdrew: Investigator discretion | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 1 | 2 |
| Withdrew: Randomized, but did not receive treatment | 0 | 0 | 0 | 0 | 1 |
The Early Bactericidal Activity was determined by change in log10CFU/mL of sputum over the period Baseline to Day 14. Log(CFU) was calculated as: Log(CFU/mL)=log10(mean\[Total count 1:Total Count 2\]\*2\*5\*10\^Dilution); where total counts 1 and 2 were bacterial counts from plates 1 and 2 respectively; \*2 represents the 1:1 dilution of the original specimen and \*5 represents the 0.2 mL (200 microliter) inoculation of the specimen; Dilution is the dilution factor for that plate. Baseline (Day 0) was defined as the mean of Day -2 and Day -1; if data was available at only one of these timepoints then that value was used as Baseline.
| Log10CFU/mL | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Change in log10 Colony Forming Units (CFU) Per (/) Milliliter (mL) of Direct Respiratory Sputum Samples From Baseline to Day 14 | -0.199 ± 0.0130 | -0.017 ± 0.0182 | -0.092 ± 0.0136 | -0.092 ± 0.0142 | -0.138 ± 0.0147 |
The Early Bactericidal Activity was determined by change in log10CFU per mL of sputum over the period Baseline to Day 2. Log(CFU) was calculated as: Log(CFU/mL)=log10(mean\[Total count 1:Total Count 2\]\*2\*5\*10\^Dilution); where total counts 1 and 2 were bacterial counts from plates 1 and 2 respectively; \*2 represents the 1:1 dilution of the original specimen and \*5 represents the 0.2 mL (200 microliter) inoculation of the specimen; Dilution is the dilution factor for that plate. Baseline (Day 0) was defined as the mean of Day -2 and Day -1; if data was available at only one of these timepoints then that value was used as Baseline.
| log10CFU/mL | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Change in log10 CFU/mL of Direct Respiratory Sputum Samples From Baseline to Day 2 | -0.598 ± 0.0801 | 0.250 ± 0.1077 | -0.153 ± 0.0801 | -0.055 ± 0.0832 | -0.040 ± 0.0855 |
The Early Bactericidal Activity was determined by change in log10CFU per mL of sputum over the period Day 2 to Day 14. Log(CFU) was calculated as: Log(CFU/mL)=log10(mean\[Total count 1:Total Count 2\]\*2\*5\*10\^Dilution); where total counts 1 and 2 were bacterial counts from plates 1 and 2 respectively; \*2 represents the 1:1 dilution of the original specimen and \*5 represents the 0.2 mL (200 microliter) inoculation of the specimen; Dilution is the dilution factor for that plate.
| log10CFU/mL | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Change in log10 CFU Per mL of Direct Respiratory Sputum Samples From Day 2 to Day 14 | -0.162 ± 0.0169 | -0.037 ± 0.0233 | -0.080 ± 0.0173 | -0.086 ± 0.0181 | -0.129 ± 0.0192 |
The Early Bactericidal Activity was determined by change in TTP per mL sputum over the period Baseline to Day 14. The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) automated liquid culture system of time to positivity of Mycobacterium tuberculosis from an overnight sputum collection. Time to sputum-culture positivity was the time between sample inoculation and detection of mycobacterial growth in the mycobacterium growth indicator tube. Baseline (Day 0) was defined as the mean of Day -2 and Day -1; if data was available at only one of these timepoints then that value was used as Baseline.
| log10hours | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Change in log10 Time to Sputum Culture Positivity (TTP) From Baseline to Day 14 | 0.025 ± 0.0010 | 0.000 ± 0.0015 | 0.015 ± 0.0011 | 0.021 ± 0.0012 | 0.022 ± 0.0013 |
The Early Bactericidal Activity was determined by change in TTP per mL sputum over the period Baseline to Day 2. The TTP was measured in the MGIT automated liquid culture system of time to positivity of Mycobacterium tuberculosis from an overnight sputum collection. Time to sputum-culture positivity was the time between sample inoculation and detection of mycobacterial growth in the mycobacterium growth indicator tube. Baseline (Day 0) was defined as the mean of Day -2 and Day -1; if data was available at only one of these timepoints then that value was used as Baseline.
| log10hours | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Change in log10 TTP From Baseline to Day 2 | 0.105 ± 0.0068 | -0.003 ± 0.0096 | 0.021 ± 0.0071 | 0.032 ± 0.0072 | 0.066 ± 0.0074 |
The Early Bactericidal Activity was determined by change in TTP per mL sputum over the period Day 2 to Day 14. The TTP was measured in the MGIT automated liquid culture system of time to positivity of Mycobacterium tuberculosis from an overnight sputum collection. Time to sputum-culture positivity was the time between sample inoculation and detection of mycobacterial growth in the mycobacterium growth indicator tube.
| log10hours | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Change in log10 TTP From Day 2 to Day 14 | 0.017 ± 0.0011 | 0.001 ± 0.0016 | 0.013 ± 0.0012 | 0.017 ± 0.0012 | 0.016 ± 0.0013 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3036656.
| Hours*nanogram per milliliter | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|
| Area Under the Plasma Drug Concentration Versus Time Curve From Time Zero to Last Time of Quantifiable Concentration (AUC[0-t]) Following Once Daily Dosing of GSK3036656 | 281.8 ± 25.7 | 1495.6 ± 12.5 | 4493.8 ± 12.5 | 11505.6 ± 17.9 |
Blood samples were collected at indicated time points for PK analysis of GSK3036656.
| Hours*nanogram per milliliter | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|
| Area Under the Plasma Concentration Time Curve From Zero to 24 Hours (AUC[0-24]) Following Once Daily Dosing of GSK3036656 | 282.1 ± 25.8 | 1497.1 ± 12.4 | 4493.9 ± 12.5 | 11540.0 ± 17.8 |
Blood samples were collected at indicated time points for PK analysis of GSK3036656.
| Nanogram per milliliter | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|
| Maximum Observed Plasma Drug Concentration (Cmax) Following Once Daily Dosing of GSK3036656 | 16.93 ± 23.7 | 94.60 ± 24.7 | 291.41 ± 18.9 | 705.24 ± 20.2 |
Blood samples were collected at indicated time points for PK analysis of GSK3036656.
| Hours | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|
| Time to Reach Cmax (Tmax) Following Once Daily Dosing of GSK3036656 | 1.500 (0.50 to 6.00) | 2.492 (0.50 to 4.00) | 1.000 (0.50 to 4.00) | 2.000 (0.50 to 8.00) |
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Adverse events which were not Serious Adverse Events were considered as Non-Serious adverse events.
| Participants | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Non-SAEs | 14 | 7 | 14 | 15 | 9 |
| SAEs1 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, total neutrophils, and platelet count. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
| 10^9 cells per liter | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Basophils | -0.006 ± 0.0281 | -0.009 ± 0.0242 | -0.018 ± 0.0248 | -0.003 ± 0.0263 | -0.005 ± 0.0267 |
| Eosinophils | 0.086 ± 0.1383 | 0.075 ± 0.1135 | 0.088 ± 0.1239 | 0.072 ± 0.0880 | 0.057 ± 0.0642 |
| Lymphocytes | 0.051 ± 0.3024 | -0.066 ± 0.3066 | 0.157 ± 0.4010 | 0.099 ± 0.5175 | 0.136 ± 0.3861 |
| Monocytes | -0.073 ± 0.3236 | -0.156 ± 0.1467 | -0.125 ± 0.1376 | -0.301 ± 0.3647 | -0.242 ± 0.2225 |
| Total neutrophils | -0.940 ± 1.9563 | -0.509 ± 0.9609 | -0.613 ± 1.4654 | -1.633 ± 1.6475 | -0.949 ± 1.2011 |
| Platelet count | -59.6 ± 105.19 | -35.0 ± 83.00 | -93.6 ± 81.05 | -7.3 ± 81.33 | -78.6 ± 43.53 |
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
| Grams per liter | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Change From Baseline in Hematology Parameter: Hemoglobin | -3.4 ± 9.15 | -2.9 ± 6.64 | 0.0 ± 7.32 | 1.7 ± 9.21 | -4.6 ± 14.99 |
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
| Proportion of red blood cells in blood | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Change From Baseline in Hematology Parameter: Hematocrit | -0.012 ± 0.0308 | -0.008 ± 0.0225 | 0.003 ± 0.0247 | 0.007 ± 0.0277 | -0.018 ± 0.0454 |
Blood samples were collected to analyze the hematology parameter: red blood cells count. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
| 10^12 cells per liter | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Change From Baseline in Hematology Parameter: Red Blood Cells Count | -0.130 ± 0.3067 | -0.091 ± 0.2776 | 0.016 ± 0.2753 | 0.059 ± 0.2875 | -0.216 ± 0.6590 |
Blood samples were collected to analyze the hematology parameter: mean corpuscular volume. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
| Femtoliter | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Change From Baseline in Hematology Parameter: Mean Corpuscular Volume | 0.2 ± 1.92 | -0.3 ± 0.89 | 0.1 ± 1.36 | 0.5 ± 0.92 | 0.0 ± 1.35 |
Blood samples were collected to analyze the hematology parameter: mean corpuscle hemoglobin. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
| Picograms | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Change From Baseline in Hematology Parameter: Mean Corpuscle Hemoglobin | 0.2 ± 0.65 | -0.1 ± 0.64 | -0.1 ± 0.64 | 0.1 ± 0.70 | 0.3 ± 0.75 |
Blood samples were collected to analyze the hematology parameter: reticulocytes. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
| Percentage of reticulocytes | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Change From Baseline in Hematology Parameter: Reticulocytes | 0.0045 ± 0.00568 | 0.0035 ± 0.00245 | 0.0041 ± 0.00255 | 0.0055 ± 0.00374 | 0.0025 ± 0.00456 |
Blood samples were collected to analyze the chemistry parameters: glucose, calcium, chloride, potassium, sodium, and blood urea nitrogen. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
| Millimoles per liter | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Glucose | -0.29 ± 0.734 | 0.05 ± 0.809 | 0.17 ± 1.047 | -0.30 ± 0.902 | -0.86 ± 1.477 |
| Calcium | 0.021 ± 0.0814 | -0.018 ± 0.1007 | -0.034 ± 0.0672 | 0.005 ± 0.0633 | -0.024 ± 0.0860 |
| Chloride | 1.1 ± 2.14 | 1.0 ± 1.69 | 1.6 ± 2.59 | 2.3 ± 2.25 | 2.3 ± 3.79 |
| Potassium | -0.39 ± 0.398 | -0.79 ± 0.925 | -0.47 ± 0.403 | -0.15 ± 0.521 | -0.28 ± 0.521 |
| Sodium | 0.4 ± 2.33 | 1.0 ± 1.60 | 0.7 ± 2.55 | 2.1 ± 3.49 | 0.5 ± 3.10 |
| Blood urea nitrogen | -0.054 ± 0.3207 | -0.169 ± 0.5493 | 0.125 ± 0.3074 | 0.145 ± 0.2860 | 0.042 ± 0.3198 |
Blood samples were collected to analyze the chemistry parameters: LDH, ALT, ALP, AST and GGT. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
| International units per liter | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| LDH | -56.3 ± 57.81 | -52.8 ± 72.99 | -18.3 ± 36.22 | -26.5 ± 57.92 | -8.5 ± 73.83 |
| ALT | -20.6 ± 35.79 | -37.0 ± 62.35 | -8.1 ± 18.22 | -11.0 ± 18.60 | 5.9 ± 20.77 |
| ALP | -3.1 ± 21.22 | -34.1 ± 61.88 | -16.8 ± 32.52 | -4.0 ± 70.73 | -7.5 ± 13.06 |
| AST | -13.7 ± 22.27 | -12.9 ± 13.94 | -5.6 ± 9.86 | -8.4 ± 13.47 | 2.2 ± 8.74 |
| GGT | -3.9 ± 22.20 | -51.0 ± 76.64 | -14.9 ± 28.18 | -16.4 ± 30.83 | -5.2 ± 23.23 |
Blood samples were collected to analyze the chemistry parameters: creatinine, indirect bilirubin, direct bilirubin and total bilirubin. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
| Micromoles per liter | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Creatinine | 0.6 ± 6.09 | 2.8 ± 4.74 | 3.1 ± 9.13 | 1.5 ± 6.24 | 0.6 ± 5.08 |
| Indirect bilirubin | -1.2 ± 1.08 | -0.9 ± 1.07 | -0.1 ± 1.51 | -1.1 ± 1.71 | 0.3 ± 1.03 |
| Direct bilirubin | -0.6 ± 0.70 | -0.5 ± 1.07 | 0.0 ± 0.76 | -0.7 ± 0.90 | -0.7 ± 1.38 |
| Total bilirubin | -1.5 ± 1.34 | -1.1 ± 1.81 | -0.1 ± 1.51 | -1.7 ± 2.05 | 0.0 ± 1.58 |
Blood samples were collected to analyze the chemistry parameter: total protein. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
| Grams per liter | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Change From Baseline in Chemistry Parameter: Total Protein | -1.7 ± 3.72 | -1.0 ± 6.46 | -1.3 ± 4.73 | 2.2 ± 6.73 | -4.2 ± 5.83 |
Urine samples were collected to assess urine occult blood and urine protein. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased and increase to abnormal for urine occult blood and protein indicating proportional concentrations in the urine sample. 'No change/decreased' means no change from Baseline or a value less than the Baseline value. 'Increase to abnormal' means an increase from the Baseline value that is considered as an abnormal value. Baseline value is the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits. Data for worst-case post Baseline is presented.
| Participants | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Occult blood: No change/decrease | 15 | 9 | 16 | 14 | 9 |
| Occult blood: Increase to abnormal | 3 | 0 | 1 | 2 | 6 |
| Protein: No change/decrease | 8 | 5 | 9 | 10 | 9 |
| Protein: Increase to abnormal | 10 | 4 | 8 | 6 | 6 |
Vital signs were measured in a semi-supine or supine position after 5 minutes rest. The PCI range for vital signs were: systolic blood pressure (SBP) (lower: \<85 and upper: \>160 milliliter of mercury \[mmHg\]); diastolic blood pressure (DBP) (lower: \<45 and upper: \>100 mmHg); heart rate (lower: \<40 and upper: \>110 beats per minute \[bpm\]); respiratory rate (lower: 10 and upper: 28 breaths per minutes) and temperature (lower: \<35 and upper: \>37.9 degrees Celsius). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high), unless there was no change in their category. Participants whose value category was unchanged (e.g. High to High), or whose value became within range, were recorded in the "To w/in Range or No Change category". Participants were counted twice if the participant had values that changed "To Low" and "To High".
| Participants | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| SBP: To low | 1 | 1 | 0 | 1 | 0 |
| SBP: To within Range or No Change | 17 | 8 | 17 | 15 | 15 |
| SBP: To High | 0 | 0 | 0 | 0 | 0 |
| DBP: To low | 1 | 1 | 1 | 0 | 0 |
| DBP: To within Range or No Change | 16 | 7 | 16 | 16 | 15 |
| DBP: To High | 1 | 1 | 0 | 0 | 0 |
| Heart rate: To low | 0 | 0 | 0 | 0 | 0 |
| Heart rate: To within Range or No Change | 16 | 6 | 15 | 15 | 15 |
| Heart rate: To High | 2 | 3 | 2 | 1 | 0 |
| Respiratory rate: To low | 0 | 0 | 0 | 0 | 0 |
| Respiratory rate: To within Range or No Change | 18 | 9 | 17 | 13 | 15 |
| Respiratory rate: To High | 0 | 0 | 0 | 3 | 0 |
| Temperature: To low | 0 | 0 | 0 | 1 | 0 |
| Temperature: To within Range or No Change | 17 | 7 | 16 | 14 | 15 |
| Temperature: To High | 1 | 2 | 1 | 1 | 0 |
Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, uncorrected QT and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Abnormal findings were categorized as clinically significant and not clinically significant. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with abnormal clinically significant ECG findings for worst case post-Baseline has been presented.
| Participants | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Abnormal, not clinically significant | 13 | 5 | 12 | 12 | 10 |
| Abnormal - clinically significant | 0 | 0 | 0 | 1 | 0 |
Twelve-lead ECGs were obtained to QTcF Interval and measured QT duration corrected for heart rate by Fridericia's formula interval. Baseline value was the latest assessment prior to Day 1 dose with a non-missing value, including those from unscheduled visits and the mean of the triplicate measurements at any given time point was used as the value for that time point. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit (Day 14) value.
| Milliseconds | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF) | 6.4 ± 13.64 | 11.3 ± 14.40 | -1.8 ± 20.48 | 9.5 ± 14.91 | 4.0 ± 16.76 |
Collected over All-cause mortality, SAEs and non-SAEs were collected up to Day 28 (follow-up visit). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rifafour e-275 | 0/18 (0%) | 0/18 (0%) | 14/18 (77.8%) |
| GSK3036656 1 mg | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| GSK3036656 5 mg | 0/17 (0%) | 0/17 (0%) | 14/17 (82.4%) |
| GSK3036656 15 mg | 0/16 (0%) | 0/16 (0%) | 15/16 (93.8%) |
| GSK3036656 30 mg | 0/15 (0%) | 0/15 (0%) | 9/15 (60%) |
| Event | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg |
|---|---|---|---|---|---|
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 2/18 | 0/9 | 5/17 | 2/16 | 1/15 |
| PruritusSkin and subcutaneous tissue disorders | 2/18 | 2/9 | 1/17 | 4/16 | 0/15 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/18 | 0/9 | 1/17 | 4/16 | 0/15 |
| HeadacheNervous system disorders | 3/18 | 2/9 | 1/17 | 2/16 | 1/15 |
| Abdominal painGastrointestinal disorders | 3/18 | 0/9 | 0/17 | 0/16 | 2/15 |
| VomitingGastrointestinal disorders | 0/18 | 0/9 | 1/17 | 1/16 | 2/15 |
| NauseaGastrointestinal disorders | 2/18 | 0/9 | 0/17 | 2/16 | 0/15 |
| Rash papularSkin and subcutaneous tissue disorders | 1/18 | 0/9 | 0/17 | 2/16 | 0/15 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/18 | 1/9 | 0/17 | 2/16 | 0/15 |
| DiarrhoeaGastrointestinal disorders | 1/18 | 0/9 | 2/17 | 0/16 | 0/15 |
Safety Population consisted of all randomized participants who received at least one dose of study treatment.
| Age, Continuous(Years) | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 37.0 ± 10.20 | 37.8 ± 8.38 | 38.1 ± 10.33 | 39.8 ± 12.33 | 38.5 ± 9.82 | 38.2 ± 10.22 |
| Sex: Female, Male(Participants) | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 18 | 9 | 17 | 16 | 15 | 75 |
| Race/Ethnicity, Customized(Participants) | Rifafour e-275 | GSK3036656 1 mg | GSK3036656 5 mg | GSK3036656 15 mg | GSK3036656 30 mg | Total |
|---|---|---|---|---|---|---|
| Black or African American | 18 | 9 | 17 | 16 | 15 | 75 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Mar 2019 to primary completion in Dec 2021, 32 months.
Results were first posted in Oct 2023, 1 year 10 months after primary completion.
Of 43 phase 2 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 37. This study's 32 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK656